Recombinant Human IL6RA protein, Fc-tagged
Cat.No. : | IL6RA-345H |
Product Overview : | Recombinant Human IL6RA protein (Leu20-Pro365), fused to human IgG1 Fc tag at C-terminus, was expressed in human 293 cells (HEK293). |
- Specification
- Gene Information
- Related Products
Description : | Interleukin 6 receptor (IL6R) is also known as CD126 (Cluster of Differentiation 126), is a potent pleiotropic cytokine that regulates cell growth and differentiation of various tissues, and is known particularly for its role in the immune response and acute phase reactions. IL6R is a protein complex consisting of a IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. IL6R also denotes the human gene encoding this subunit. Alternatively spliced transcript variants encoding distinct isoforms have been reported. IL6R subunit also shared by many other cytokines. The soluble form of IL6R arises from proteolytic cleavage of membrane-bound IL6Rα, and acts agonistically by making the IL6 ligand accessible to the signal transducer gp130. Dysregulated production of IL6 and IL6R are implicated in the pathogenesis of several inflammatory diseases and malignancies such as multiple myeloma, rheumatoid arthritis, or osteoporosis, and it has been reported that a humanized anti-IL6R monoclonal antibody is a promising agent applicable to the therapeutic approach for IL6 driven diseases. Interleukin-6 receptor has been shown to interact with Interleukin 6 and Ciliary neurotrophic factor. |
Source : | HEK293 |
Species : | Human |
Tag : | human IgG1 Fc |
Form : | Lyophilized from 0.22 um filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5, 10% trehalose. |
Molecular Mass : | The protein has a calculated MW of 65.0 kDa. The protein migrates as 70-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. |
Protein length : | 346 |
Endotoxin : | Less than 1.0 EU per ug by the LAL method. |
Purity : | >95% as determined by SDS-PAGE. |
Storage : | For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at: -20 centigrade to -70 centigrade for 12 months in lyophilized state; -70 centigrade for 3 months under sterile conditions after reconstitution. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4ºC before opening to recover the entire contents. |
Gene Name : | IL6RA |
Official Symbol : | IL6RA |
Synonyms : | IL6Q; gp80; CD126; IL6RA; IL6RQ; IL-6RA; IL-6R-1 |
Gene ID : | 3570 |
mRNA Refseq : | NM_000565.4 |
Protein Refseq : | NP_000556.1 |
MIM : | 147880 |
UniProt ID : | P08887 |
Products Types
◆ Recombinant Protein | ||
Il6ra-1246M | Recombinant Mouse Il6ra Protein, MYC/DDK-tagged | +Inquiry |
IL6RA-4520M | Recombinant Mouse IL6RA Protein, His (Fc)-Avi-tagged | +Inquiry |
IL6RA-3322H | Active Recombinant Human IL6RA protein | +Inquiry |
IL6RA-3324H | Active Recombinant Human IL6RA protein | +Inquiry |
IL6RA-8178M | Recombinant Mouse IL6RA Protein | +Inquiry |
◆ Lysates | ||
IL6R-2590MCL | Recombinant Mouse IL6R cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionIl6ra blocks the binding of the interleukin-6 receptor by acting on it, thereby affecting its immunomodulatory effect and reducing inflammation.
The efficacy of Il6ra is related to the severity of the disease, disease type and individual differences of patients, and should be judged by professional physicians according to the situation.
Il6ra can be used to treat rheumatoid arthritis, psoriasis, alopecia areata and other autoimmune diseases.
Almost all treatments have some kind of side effect, but the occurrence of side effects can be reduced with proper dosing and monitoring.
Recombinant Il6ra inhibits the immune response by inhibiting the cytokine activity of interleukin-6.
In addition to the autoimmune diseases mentioned above, Il6ra may also be used in the future to treat chronic inflammatory bowel disease, neurodegenerative diseases, and cancer.
Customer Reviews (3)
Write a reviewIt has good effect and stability in gene expression regulation.
Will not interact with other drugs, will not affect.
The application performance is stable in common colorimetric reactions.
Ask a Question for All IL6RA Products
Required fields are marked with *
My Review for All IL6RA Products
Required fields are marked with *
Inquiry Basket